Jefferies Financial Group Inc. Makes New $10.97 Million Investment in Ultragenyx Pharmaceutical Inc. $RARE

Jefferies Financial Group Inc. purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 477,092 shares of the biopharmaceutical company’s stock, valued at approximately $10,973,000.

A number of other large investors also recently made changes to their positions in RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 14.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after purchasing an additional 29,984 shares during the period. Creative Planning acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $454,000. American Century Companies Inc. acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $366,000. M&T Bank Corp lifted its stake in shares of Ultragenyx Pharmaceutical by 19.7% in the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock valued at $263,000 after purchasing an additional 1,192 shares during the period. Finally, Amundi lifted its stake in shares of Ultragenyx Pharmaceutical by 1,560.4% in the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock valued at $3,913,000 after purchasing an additional 93,189 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group cut their price target on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Barclays cut their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. Truist Financial raised Ultragenyx Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. Guggenheim cut their price target on Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Wedbush cut their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $59.88.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $23.39 on Monday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $42.37. The company has a fifty day simple moving average of $23.22 and a 200 day simple moving average of $26.07. The stock has a market cap of $2.30 billion, a P/E ratio of -3.83 and a beta of 0.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The firm had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. During the same quarter in the prior year, the company earned ($1.57) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was down 2.2% on a year-over-year basis. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.62 earnings per share for the current fiscal year.

Insider Activity

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 10,029 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $228,661.20. Following the completion of the transaction, the insider owned 110,026 shares in the company, valued at approximately $2,508,592.80. This represents a 8.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Erik Harris sold 10,539 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $240,289.20. Following the transaction, the executive vice president owned 89,515 shares of the company’s stock, valued at approximately $2,040,942. This trade represents a 10.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 117,262 shares of company stock worth $2,687,403. 5.20% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.